CDO at OKYO Pharma Ltd (OKYO) buys 3,500 shares in open market
Rhea-AI Filing Summary
OKYO Pharma Ltd reported an amended insider transaction for Chief Development Officer Gary S Jacob. The amendment only corrects the code for an open market purchase on July 21, 2026, when he bought 3,500 common shares at $1.40, increasing his direct holdings to 112,420 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 3,500 shares
Net Buy
1 txn
Insider
JACOB GARY S
Role
CHIEF DEVELOPMENT OFFICER
Bought
3,500 shs ($5K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | COMMON STOCK | 3,500 | $1.40 | $5K |
Holdings After Transaction:
COMMON STOCK — 112,420 shares (Direct)
Key Figures
Shares purchased: 3,500 shares
Purchase price: $1.40 per share
Post-transaction holdings: 112,420 shares
3 metrics
Shares purchased
3,500 shares
Open market common stock purchase on July 21, 2026
Purchase price
$1.40 per share
Price for common stock bought on July 21, 2026
Post-transaction holdings
112,420 shares
Direct common stock owned by Gary S Jacob after the purchase
Key Terms
open market purchase, Form 4/A, non-derivative
3 terms
open market purchase financial
"correct the transaction code associated with this open market purchase"
An open market purchase is when a company buys its own shares on public stock exchanges the same way any investor would, rather than through a private deal. Investors care because these purchases reduce the number of shares available, can boost earnings per share and share price, signal that management thinks the stock is undervalued, and use company cash that might otherwise go to reinvestment or dividends — like a business quietly buying back its own tickets at the box office.
Form 4/A regulatory
"This Form 4/A amends the Form 4 filed on July 23, 2026"
Form 4/A is an amended filing that corrects or updates an earlier Form 4, the mandatory report that insiders (like company executives, directors, or large shareholders) must file when their ownership stakes change. Think of it as an edited receipt showing who bought or sold stock and when; investors use it to track insider confidence, detect potential conflicts, and spot trading patterns that might signal future company prospects.
non-derivative financial
"transaction_type: non-derivative for the common stock purchase"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did OKYO (OKYO Pharma Ltd) report in this Form 4/A?
The amended report shows an open market purchase of 3,500 OKYO Pharma common shares at $1.40 per share on July 21, 2026, by Chief Development Officer Gary S Jacob, classified as a non-derivative transaction.
Why was the OKYO (OKYO Pharma Ltd) insider report amended?
The amendment corrects only the transaction code for the previously reported open market purchase. It states that no other reported transactions are affected, so the underlying share amount, price, and holdings remain unchanged.
Was the OKYO (OKYO Pharma Ltd) insider trade made under a Rule 10b5-1 plan?
No. The report’s Rule 10b5-1 checkbox is marked false, indicating the 3,500-share open market purchase at $1.40 per share was not executed pursuant to a Rule 10b5-1 trading plan.
What type of security and transaction is reported for OKYO (OKYO Pharma Ltd)?
The transaction involves common stock of OKYO Pharma in a non-derivative open market purchase. On July 21, 2026, the insider acquired 3,500 shares at $1.40 per share, increasing his reported direct holdings.